close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

73.07 -1.85 (-2.47%)
Official Closing Price Updated: 4:15 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
33 34 Next >
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies. 
Via The Motley Fool
5 Reasons to Buy Vertex Pharmaceuticals Now
Vertex shares are extending last year's gains, and that trend probably isn't over. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex is heading for a new phase of growth. 
Via The Motley Fool
Expert Ratings for CRISPR Therapeutics
 
Via Benzinga
3 Smart Stocks to Buy if a Recession Is on the Way
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool
CRISPR Therapeutics Stock: Bull vs. Bear
Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market? 
Via The Motley Fool
7 Biotech Stocks That Will Make You Rich in 10 Years
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years. 
Via InvestorPlace
2 Stocks Down More Than 25% to Buy Right Now
These companies are set for a new era of growth. 
Via The Motley Fool
5 Potentially Explosive Stocks to Buy in 2023
These stocks all dropped in the double digits last year. But their future prospects are brilliant. 
Via The Motley Fool
More Likely to 5X First: CRISPR Therapeutics vs. InMode
These two companies are in very different situations but could generate significant returns for investors. 
Via The Motley Fool
2 Growth Stocks You May Regret not Buying Right Now
At their beaten-down valuations, these stocks have the potential to deliver some impressive returns. 
Via The Motley Fool
Can Cathie Wood Bounce Back in 2023?
Wood sticks by her strategy, no matter what the general market does. 
Via The Motley Fool
2 Supercharged Stocks to Buy Right Now That Could Soar in 2023
These stocks have been solid performers despite the macroeconomic uncertainties in 2022. 
Via The Motley Fool
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
These biotechnology stocks are pushing ahead with promising innovations. 
Via The Motley Fool
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams. 
Via Benzinga
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over Time
Wood is bargain hunting now. And these buys may pay off big in the long run. 
Via The Motley Fool
3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street
These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
These two biotechs are flying high right now. 
Via The Motley Fool
5 Unstoppable Trends to Invest $5,000 in for 2023
These trends won't fade away, and some of the companies that are positioned to ride them should be big winners. 
Via The Motley Fool
Could CRISPR Therapeutics Help You Become a Millionaire?
The gene-editing stock still has plenty of promise. 
Via The Motley Fool
Is Vertex Pharmaceuticals a Buy?
There's more growth ahead for this biotech giant. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today